Financial Instruments and Fair Value Measurement (Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	May. 14, 2014
Recurring basis | Quoted Price in Active Markets for Identical Assets (Level 1)
Assets:
Available-for-sale securities	$ 1,235.9	$ 1,051.3
Total assets	1,235.9	1,051.3
Liabilities:
Contingent value rights	(51.9)	(136.3)
Total liabilities	(51.9)	(136.3)
Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale securities	435.7	2,373.8
Forward currency contracts	606.0	550.7
Purchased currency options	46.7	9.8
Interest rate swaps	52.5	20.0
Total assets	1,140.9	2,954.3
Liabilities:
Written currency options	(19.1)	(4.6)
Total liabilities	(19.1)	(4.6)
Recurring basis | Significant Unobservable Inputs (Level 3)
Liabilities:
Other acquisition related contingent consideration	(1,521.5)	(1,279.0)
Total liabilities	(1,521.5)	(1,279.0)
Recurring basis | Fair Value
Assets:
Available-for-sale securities	1,671.6	3,425.1
Forward currency contracts	606.0	550.7
Purchased currency options	46.7	9.8
Interest rate swaps	52.5	20.0
Total assets	2,376.8	4,005.6
Liabilities:
Contingent value rights	(51.9)	(136.3)
Written currency options	(19.1)	(4.6)
Other acquisition related contingent consideration	(1,521.5)	(1,279.0)
Total liabilities	(1,592.5)	$ (1,419.9)
Gloucester Pharmaceuticals, Inc.
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	120.0
Avila Therapeutics, Inc.
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	555.0
Quanticel
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	385.0
Nogra Pharma Limited
Fair Value of assets and liabilities
Estimated maximum potential payments related to contingent consideration	$ 1,865.0		$ 815.0